Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bellvitge Biomedical Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9407
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center that offers health care development solutions. The center conducts clinical and basic research for developing treatments and techniques to improve health care. It offers its research work in the fields of neurosciences, infectious pathology and transplants, cancer and human molecular genetics, growth factors, inflammatory, chronic and degenerative diseases, hormones and diabetes, epigenetics and cancer biology. IDIBELL also conducts translational medicine research for aspects of neurosciences, biomedicine, mainly cancer, and other prevalent diseases. The center manages the research of oncology institutions, universities, and other healthcare facilities. IDIBELL is headquartered in Barcelona, Spain.

Bellvitge Biomedical Research Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute – Key Competitors 15
Bellvitge Biomedical Research Institute – Key Employees 16
Bellvitge Biomedical Research Institute – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Legal and Regulatory 18
Mar 23, 2018: IDIBELL obtains the TECNIO certification as a public technology facilitator 18
Government and Public Interest 19
Sep 25, 2018: IDIBELL researchers receive AECC grants on World Cancer Research Day 19
Aug 11, 2018: A new epigenetic signature predicts the response to immunotherapy in lung cancer 21
Aug 01, 2018: The biochemical signature of the synapse in a model of Down syndrome is identified with high resolution 22
Jun 27, 2018: New combined treatment shows promise in Hepatocellular Carcinoma 23
Jun 11, 2018: New epigenetic drug against Mantle Cell Lymphoma 24
May 14, 2018: Scientists discover a variation of the genome predisposing to Alzheimer’s disease 25
Apr 20, 2018: The EPICUP Project receives a Pfizer Foundation Innovation award 26
Apr 05, 2018: A potential new therapeutic target for Ewing sarcoma 27
Mar 15, 2018: Creation of a web platform for the identification of fronto-subcortical connectivity alterations in brain disorders 28
Feb 20, 2018: RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease 29
Jan 31, 2018: EU empowers four IDIBELL researchers with Marie Sklodowska-Curie Individual Fellowships 31
Jan 04, 2018: IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer 32
Jan 04, 2018: IDIBELL researchers – ICO identify a new therapeutic target to combat metastasis in ovarian cancer 33
Jan 02, 2018: Alex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer 34
Dec 19, 2017: Mild obsessive-compulsive symptoms are associated with variations of cerebral anatomy in healthy children 35
Dec 18, 2017: European project EU-TRAIN to improve the results in kidney transplant receives more than six million euros 36
Nov 21, 2017: The isoforms of the HP1 protein differentially regulate the organization and structure of heterochromatin 37
Oct 09, 2017: A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer 38
Oct 03, 2017: IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients 39
Jan 31, 2017: European experts highlight the potential of xenografts in personalized oncology 40
Product News 41
Jun 07, 2018: First photoactive drug to fight Parkinson’s disease 41
May 09, 2018: A new drug shows preclinical efficacy in Rett syndrome 43
Apr 11, 2017: First photoactive drug for pain treatments 44
Jan 11, 2018: ICO-IDIBELL researchers successfully test a new combination therapy in sarcomas 46
Jan 11, 2018: IDIBELL researchers successfully test a new combination therapy in sarcomas 47
Other Significant Developments 48
Jun 22, 2018: CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Key Facts 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute, Key Competitors 15
Bellvitge Biomedical Research Institute, Key Employees 16

List of Figures
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Paranta Biosciences Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Paranta Biosciences Ltd (Paranta Biosciences) is a clinical stage biopharmaceutical company which develops follistatin-based bio-therapeutic for the treatment of inflammatory and fibrotic diseases. The company’s lead product candidate PB01, a recombinant human follistatin-288 is under phase …
  • Jiangsu Hengrui Medicine Co Ltd (600276):製薬・医療:M&Aディール及び事業提携情報
    Summary Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture and distribution of novel pharmaceutical products. Its product portfolio includes antineoplastic products, anti-tumor drugs, surgical drugs and contrast age …
  • Carl Zeiss AG:医療機器:M&Aディール及び事業提携情報
    Summary Carl Zeiss AG (Carl Zeiss) is a medical technology with focus on optical and optoelectronic industry. It develops and distributes lithography optics, measuring technology, photomask systems, microscopes, medical technology products including ophthalmic diagnostic and therapeutic products, ey …
  • Screen Holdings Co., Ltd. (7735):企業の財務・戦略的SWOT分析
    Screen Holdings Co., Ltd. (7735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • SBM Offshore NV (SBMO)-石油・ガス分野:企業M&A・提携分析
    Summary SBM Offshore N.V. (SBM Offshore) is a floating production solutions provider for offshore oil and gas industry. The company designs supplies, installs and operates Floating Production, Storage and Offloading (FPSO) vessels. The company leases its FPSO vessels to its clients. It also undertak …
  • Camaieu:企業の戦略・SWOT・財務情報
    Camaieu - Strategy, SWOT and Corporate Finance Report Summary Camaieu - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nippon Seiro Co., Ltd. (5010):企業の財務・戦略的SWOT分析
    Nippon Seiro Co., Ltd. (5010) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Clean Energy Finance Corp:電力:M&Aディール及び事業提携情報
    Summary Clean Energy Finance Corp (CEFC) is a statutory authority that provides investments for clean energy projects including renewable energy, energy efficiency and low emissions technologies. The authority financing structures include project finance, climate bonds and equity funds, aggregation …
  • University of Utah-製薬・医療分野:企業M&A・提携分析
    Summary University of Utah (University of Utah) is a research university that offers various undergraduate and postgraduate programs. The university offers educational programs in various fields such as architecture and planning, engineering, fine arts, health, humanities, law, medicine, business, d …
  • Takenaka Corporation:企業の戦略・SWOT・財務情報
    Takenaka Corporation - Strategy, SWOT and Corporate Finance Report Summary Takenaka Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • 8point3 Energy Partners LP (CAFD):電力:M&Aディール及び事業提携情報
    Summary 8point3 Energy Partners LP (8point3 Energy) is a renewable energy company that owns, operates and acquires solar energy generation projects. The company offers operation and maintenance, project development, and technical services. It operates residential, commercial, industrial, and utility …
  • MOL Hungarian Oil and Gas Plc (MOL):企業の財務・戦略的SWOT分析
    MOL Hungarian Oil and Gas Plc (MOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nuvia Ltd:企業の戦略的SWOT分析
    Nuvia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • NETGEAR Inc (NTGR):企業の財務・戦略的SWOT分析
    NETGEAR Inc (NTGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Global Marine Systems Ltd:企業の戦略的SWOT分析
    Global Marine Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nayara Energy Ltd:企業の戦略的SWOT分析
    Nayara Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Sitara Chemical Industries Ltd (SITC):企業の財務・戦略的SWOT分析
    Sitara Chemical Industries Ltd (SITC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Titan Pharmaceuticals Inc (TTNP)-医療機器分野:企業M&A・提携分析
    Summary Titan Pharmaceuticals Inc (Titan) is a biopharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio offers prob …
  • The Scripps Research Institute-医療機器分野:企業M&A・提携分析
    Summary The Scripps Research Institute (TSRI) is a research and educational organization that conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The institut …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆